{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"57"}]}],"title":"ECOG PS = 0"},{"categories":[{"measurements":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"118"}]}],"title":"ECOG PS = 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"44"}]}],"title":"ECOG PS >1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"219"}],"units":"Participants"}],"description":"ECOG performance status was measured on an 6 point scale. 0-Fully active, able to carry on all pre-disease performance without restriction.\n\n1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.\n2. Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours.\n3. Capable of only limited self-care, confined to bed or chair more than 50% of waking hours.\n4. Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair.\n5. Dead. Number of participants with ECOG PS was reported.","groups":[{"description":"Participants received 1.25 mg/kg of body weight enfortumab vedotin by IV infusion over approximately 30 minutes on days 1, 8 and 15 of every 28-day cycle. Participants received study treatment until radiological disease progression as determined per investigator assessment or other discontinuation criteria were met or upon study termination, or study completion, whichever occurred first.","id":"OG000","title":"Enfortumab Vedotin 1.25 mg/kg"},{"description":"Participants received either 75 mg/m\\^2 docetaxel by IV infusion over approximately 1 hour or 320 mg/m\\^2 vinflunine by IV infusion over approximately 20 minutes or 175 mg/m\\^2 paclitaxel by IV infusion over approximately 3 hours on day 1 of every 21-day cycle. Participants received study treatment until radiological disease progression as determined per investigator assessment or other discontinuation criteria were met or upon study termination, or study completion, whichever occurred first.","id":"OG001","title":"Chemotherapy"}],"paramType":"NUMBER","populationDescription":"Safety population with available data.","reportingStatus":"POSTED","timeFrame":"End of treatment (EOT) (Median (range) time on study drug was 4.99 (0.5, 19.4) months in enfortumab vedotin and 3.45 (0.2, 15.0) months in chemotherapy group)","title":"Number of Participants With ECOG Performance Status","type":"SECONDARY","unitOfMeasure":"participants"}